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Abstract
Purpose: Measurements of non-displaceable binding (VND) of positron emission tomography (PET)
ligands are not often made in vivo in humans because they require ligands to displace binding to target
receptors and there are few readily available, safe ones to use. A technique to measure VND for ligands
for the 18-kDa translocator protein (TSPO) has recently been developed which compares the total
volume of distribution (VT) before and after administration of the TSPO ligand XBD173. Here, we used
XBD173 with an occupancy plot to quantify VND for two TSPO radiotracers, [
18F]GE-180 and
[11C]PBR28, in cohorts of people with multiple sclerosis (MS). Additionally, we compared plots of
subjects carrying high (HAB) or mixed binding (MAB) affinity polymorphisms of TSPO to estimate VND
without receptor blockade.
Procedures: Twelve people withMS underwent baselineMRI and 90-min dynamic [18F]GE-180 PET or
[11C]PBR28 PET (n=6; three HAB, three MAB each). Arterial blood sampling was used to generate
plasma input functions for the two-tissue compartmentmodel.VNDwas calculated using two independent
methods: the occupancy plot (bymodelling the differences in signal post XBD173) and the polymorphism
plot (by modelling the differences in signal across presence and absence of rs6971 genotypes).
Results: Whole brainVT (mean ± standard deviation) was 0.29± 0.17ml/cm
3 for [18F]GE-180 and 5.01
±1.88 ml/cm3 for [11C]PBR28. Using the occupancy and polymorphism plots respectively, VND for
[18F]GE-180 was 0.11 ml/cm3 (95 % CI =0.02, 0.16) and 0.20 ml/cm3 (0.16, 0.34), accounting for, on
average, 55% ofVT in the whole brain. For [
11C]PBR28, these values were 3.81ml/cm3 (3.02, 4.21) and
3.49 ml/cm3 (1.38, 4.27), accounting for 67 % of average whole brain VT.
Sujata Sridharan and Joel Raffel are joint first authors.
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Conclusions: Although VT for [
18F]GE-180 is low, indicating low brain penetration, half the signal
shown by MS subjects reflected specific TSPO binding. VT for [
11C]PBR28 was higher and two
thirds of the binding was non-specific. No brain ROIs were devoid of specific signal, further
confirming that true reference tissue approaches are potentially problematic for estimating TSPO
levels.
Key words: PET, Occupancy plot, Polymorphism plot, Multiple sclerosis, [18F]GE-180,
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Introduction
Several positron emission tomography (PET) ligands
exist for the 18-kDa translocator protein (TSPO), which
can be upregulated in the mitochondria of activated
microglia when the central nervous system becomes
inflamed (see [1] for review). Currently, it is unclear,
in humans, what proportion of the observed in vivo PET
signal represents specific TSPO binding and what
proportion is merely non-displaceable binding. This is a
particular problem with TSPO imaging as (1) the binding
of a large majority of TSPO ligands is affected by
carriage of a single nucleotide polymorphism (SNP
rs6971) and (2) affinity thus varies according to whether
participants are homozygotic (high or low affinity
binders, HABs/LABs) or heterozygotic (mixed affinity
binders, MABs). This results in increased tracer-specific
variability across cohorts [2]. TSPO is known to be
expressed ubiquitously throughout the human brain,
meaning that there is no suitable reference region (free
of specific binding) which would allow the non-
displaceable proportion of the signal to be estimated
in vivo (see [3] for overview). Assuming that the fraction
of non-displaceable binding is negligible can dramatically
affect the interpretation of results. It is therefore
important to investigate the proportion of binding that
is specific for each TSPO tracer [4, 5].
Approaches recently described by Owen et al. [6] and
Guo et al. [7] can be used to estimate the non-displaceable
component of the total volume of distribution (VND) in vivo.
In short, for the TSPO ligand of interest, the total volume of
distribution, VT, is calculated both before and after blockade
with the TSPO ligand XBD173. VND is derived from the x-
intercept of the graph of V baselineT against V
baseline
T −V
block
T (see
‘Materials and Methods’). In addition, use of a polymor-
phism plot (Guo, et al. [8]), which assumes that MABs
express an equal percentage of high and low affinity binding
sites [6, 9], allows VND to be derived from the x-intercept of
VHABT against V
HAB
T −V
MAB
T (see ‘Materials and Methods’).
One recently developed ligand, [18F]GE-180, has
exhibited a higher signal to background ratio than (R)-
[11C]PK11195 in several preclinical models [10–12].
However, in human studies, it has shown unexpectedly
low brain penetration [13–15]. Additionally, in vitro data
shows that binding of [18F]GE-180 to TSPO is sensitive
to the presence of the rs6971 SNP [2, 9, 16]; however,
in these in vivo human studies, the expected genotype
dependence of signals was not observed [13, 14]. This
phenomenon may be due to poor extraction of [18F]GE-
180 over the blood−brain barrier (BBB) and/or the action
of active efflux pumps such as P-glycoprotein. Given
these unexpected results, we wished to clarify the
proportion of [18F]GE-180 uptake detected with PET in
the human brain that is non-displaceable. A recent
blocking study in healthy control subjects confirmed the
presence of specific binding throughout the human brain
with [11C]PBR28 [6]. Here, we describe a similar
blocking study to investigate whether (and what propor-
tion of) [18F]GE-180 and [11C]PBR28 PET signal is
specific to TSPO binding in people with multiple
sclerosis (MS).
Materials and Methods
Participants
Twelve people with clinically definite MS according to
revised 2010 MacDonald criteria were recruited from the
Imperial College Healthcare NHS Trust. The participants
were aged between 20 and 50 years old and provided written
informed consent, under ethics reviewed by the London
Riverside Research Ethics Committee (REC reference 14/
LO/0343 [18F]GE-180-scanned participants, 13/LO/1916
[11C]PBR28-scanned participants).
Participants attended a screening visit, including clinical
ratings with the expanded disability status scale (EDSS) [17]
and the collection of blood, to establish TSPO SNP
genotype. Predicted LABs were excluded. Participants
returned for a baseline visit where they underwent MRI
and a 90-min dynamic [18F]GE-180 or [11C]PBR28 PET
scan. One week later [18F]GE-180, or on the afternoon of the
same day [11C]PBR28, participants returned for a ‘post-
blockade’ scan; they were administered a 90-mg oral dose of
XBD173 2 h prior to a repeat PET scan with the same tracer
and dose as previously administered. The dose of 90 mg was
selected based on that previously calculated by Owen et al.
in a blocking study using [11C]PBR28 to achieve at least
75 % XBD173 occupancy in adult participants [6].
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Arterial Plasma Measurement
Participants had radial artery cannulation and blood was
withdrawn continuously at a target rate of 2.5 ml min−1 from
the start of each scan for the first 15 min. In addition,
discrete blood samples were drawn at 0, 5, 10, 15, 30, 50, 70
and 90 min ([18F]GE-180) or 0, 5, 10, 15, 20, 25, 30, 40, 50,
60, 70, 80 and 90 min ([11C]PBR28) for metabolite analysis.
For [18F]GE-180, tracer concentrations in whole blood and
plasma were measured in a well counter and radiometabolite
analysis performed using two high performance liquid
chromatography (HPLC) systems (Agilent 1260 Infinity
and Agilent 110 Series) in isocratic mode. Briefly, samples
were spun down to obtain plasma, which was then added to
HPLC-grade acetonitrile to precipitate proteins. After cen-
trifugation, the samples were rotary evaporated and analytes
collected and reconstituted in 7 % ethanol solution and
filtered in 15-mm syringe filters with a nylon membrane of
pore size 0.2 μm. For [11C]PBR28, methods described by
Owen et al. [6] were used to determine the parent fraction of
tracer in plasma and whole blood.
Scanning Protocol
All participants scanned with [18F]GE-180 underwent MR
scans on a 3-T Siemens Magnetom MR B19 scanner,
including T1 magnetisation prepared rapid gradient echo
(MPRAGE) sequences. [18F]GE-180 was synthesised, as
previously described, on a FastLab™ platform [18]. A low-
dose CT scan was performed for attenuation correction
immediately prior to a 90-min dynamic PET scan on a
Siemens Biograph 6 with a field of view of 168 × 168 ×
148 mm3. The tracer was injected as an intravenous bolus
over the course of 30 s with a target dose of 185 MBq. List-
mode data were histogrammed into 24 frames (6 × 15 s, 3 ×
60 s, 5 × 120 s, 5 × 300 s and 5 × 600 s) and reconstructed
using filtered back projection (FBP) with a ramp filter.
Reconstructed voxel size and spatial resolution were 1.57 ×
1.57 × 1.92 and ~ 5 mm, respectively. For participants
scanned with [11C]PBR28, MR scans were performed on a
Siemens Magnetom Trio scanner, while PET scans were also
performed on a Siemens Biograph 6, with list-mode data
histogrammed into 26 frames (8 × 15 s, 3 × 60 s, 5 × 120 s,
5 × 300 s and 5 × 600 s) and reconstructed using FBP with a
5-mm Gaussian filter. For [18F]GE-180 scans, the tracer was
injected 30 s after scan start time (two fewer frames in the
reconstruction).
Image Analysis
PET images underwent frame-to-frame realignment and
were coregistered with T1 MRI in PMOD (v3.6, PMOD
Technologies Ltd., Switzerland). Coregistrations were qual-
ity checked manually. MRI was used to segment the brain
into 83 regions using the Hammers atlas [19]. These regions
were inspected manually for overlap and edited where
necessary to minimise spillover from large-vessel vascular
activity. Respective smaller ROIs were then combined to
create final bilateral ROIs as follows: frontal, temporal,
parietal and occipital lobes (FL, TL, PL, OL), striatum,
putamen, thalamus, cerebellum, corpus callosum, brainstem,
whole brain (WB) and normal appearing white matter
(NAWM). Lesions were defined semi-automatically on
MRI using a local thresholding technique implemented in
in-house software (BioMedIA group, Department of Com-
puting, Imperial College London). T1, T2 fluid attenuated
inversion recovery (FLAIR), double inversion recovery
(DIR) and phase sensitive inversion recovery (PSIR)
sequences were used to maximise sensitivity of lesion
identification. All ROIs excluded lesions.
Kinetic Analysis
All kinetic analysis was performed in PMOD. Calibrated
continuous and discrete blood data were corrected for decay
and the parent fraction of tracer in plasma was calculated for
each discrete sample. Plasma over blood (POB) ratios were
calculated and the parent fraction of tracer in plasma fitted to
a Watabe parent fraction model [20] of the form
f parent tð Þ ¼ f p: 1
1− A
B
u
uBþC
 
8<
:
9=
;, where fp is the free fraction of
parent tracer and A, B, C and u are constants. This was
multiplied with the continuous whole blood data to produce
a metabolite-corrected arterial plasma input function. VT was
calculated from the unconstrained two-tissue compartment
model as previously described [13, 14].
Calculating the Component of Non-Displaceable
Binding
Three methods were used to determine the non-displaceable
(VND) and displaceable (VS) components of the total volume
of distribution (VT). Of these methods, two were indepen-
dent: the occupancy plot (methods 1a and 1b) and the
polymorphism plot (method 2).
Method 1a: Occupancy Plot with Individual VND
The occupancy plot is an adaptation of the Lassen plot
described by Cunningham et al. [4]. Given that V baselineT
¼ V S þ VND (basel ine condi t ion) and V blockT ¼ V S
1−Occdrug
 þ VND (block condition), it follows that
V baselineT −V
block
T ¼ Occdrug: V baselineT −VND
 
: Thus, plotting
V baselineT against V
baseline
T −V
block
T allows derivation of VND (x-
intercept) and the occupancy of XBD173 (slope). This
method assumes that VND is the same at pre and post-block
time points and that the fractional occupancy of XBD173
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does not change across the brain. Method 1a plots these data
for each individual participant.
Method 1b: Occupancy Plot with Constrained VND
In order to calculate a group VND, data from individual
participants were plotted as described in method 1a, with the
x-intercept forced to a best fit for all participants. This was
done by constraining the x-intercept (VND) to be equal (for
all participants) on a group level, using a linear regression
implemented in Matlab (R2018a, The MathWorks, Inc.,
MA, USA).
Method 2: Polymorphism Plot
The polymorphism plot, described by Guo et al. [7], does
not require pharmacological blockade. Instead, it relies upon
the assumption that MABs express 50 % HAB and 50 %
LAB binding sites [6, 9]. Thus, similarly to methods 1a and
1b, VHABT −V
MAB
T ¼ Δ VHABT −VND
 
, where Δ is a constant
(BP
HAB
ND −BP
MAB
ND
BPHABND
Þ relating to the non-displaceable binding poten-
tial, BPND, for HABs and LABs, respectively. Again, a plot
of VHABT against V
HAB
T −V
MAB
T thus gives VND as the x-
intercept.
Statistics
Linear regressions were generated in Matlab (R2018a, The
MathWorks, Inc., MA, USA) and VT and VND results are
expressed as mean ± standard deviation (SD). For each
tracer, VTs in different ROIs were compared using repeated
measures one-way ANOVA with a Tukey test for multiple
comparisons. Statistical tests were performed in GraphPad
Prism (v7, GraphPad Software, Inc., San Diego, CA, USA).
Results
Demographics
The mean age of participants scanned with [18F]GE-180 was
46.8 ± 9.1 years, mean age of onset was 36.2 ± 12.8 years
and EDSS ranged between 3.5 and 7.5. For [11C]PBR28,
mean age was 40.5 ± 9.0 years (unpaired t test: p = 0.25, not
significant, ns, compared to [18F]GE-180), mean age of
onset was 35.4 ± 6.2 years (p = 0.78, ns compared to
[18F]GE-180) and EDSS ranged between 1 and 6.5 (p =
0.13, ns compared to [18F]GE-180). All participants had
been treated with disease-modifying therapy. Participant
demographics are summarised in Table 1.
Visual Assessment of PET Reveals Blockade of
TSPO
Sixty- to 90-min sum PET images were generated for all
participants. There was little obvious visual difference in
sum PET images pre- and post-block (e.g., participants F
and H, Figs. 1 and 2, right hand side) for participants
scanned with [18F]GE-180 but a small decrease was evident
with [11C]PBR28. VTs were then generated for all partici-
pants in all Hammers atlas ROIs and visualised as a heat
map (left hand side, Figs. 1 and 2). In contrast to sum PET
images, there were clear visual differences between pre- and
post-block VTs with both tracers.
[18F]GE-180 Binds Specifically to TSPO
Mean whole brain baseline VT was 0.29 ± 0.17 ml/cm
3 for
[18F]GE-180 and 5.31 ± 1.53 for [11C]PBR28. There were
no significant differences in VT between any ROIs for
[18F]GE-180. For [11C]PBR28, the putamen was elevated
over NAWM (p = 0.03).
Blockade with XBD173 confirmed that both [18F]GE-180
and [11C]PBR28 exhibit specific binding in theMS brain. Of the
Table 1.. Summary of participant demographics for those scanned with [18F]GE-180 and [11C]PBR28
Tracer Participant HAB/MAB Sex Age/age at onset (years) EDSS Previous DMTs; current DMT
[18F]GE-180 A HAB M 43/32 6.5 GA; GA
B MAB M 53/36 4.0 IVIG, natalizumab; IVIG
C MAB F 60/47 3.5 Alemtuzumab; alemtuzumab
D HAB F 33/20 5.5 IB-1a/1b, natalizumab, alemtuzumab, AHSCT; natalizumab
E MAB F 46/38 6.0 IB-1a, GA, fingolimod, natalizumab; alemtuzumab
F HAB M 46/32 7.5 Natalizumab; AHSCT
[11C]PBR28 G HAB F 44/40 6.5 Natalizumab; natalizumab
H MAB M 29/27 1.0 DF; DF
I MAB F 39/30 6.5 Alemtuzumab, MSCT, natalizumab; MCTD
J MAB F 56/44 4.0 Natalizumab, AHSCT, IB-1a; nil
K HAB M 37/35.5 1.5 DF; nil
L HAB M 38/36 1.5 DF; nil
HAB/MAB high/mixed affinity binder, EDSS (Kurtzke) expanded disability status scale, DMT disease modifying therapy, GA glatiramer acetate, IVIG
intravenous immunoglobulin, IB interferon-beta, AHSCT autologous haematopoietic stem cell transplantation, DF dimethyl fumarate, MSC mesenchymal stem
cell therapy, MCTD mixed connective tissue disease
Sridharan S. et al.: [18F]GE-180 Specific Binding
12 participants, one displayed no measureable occupancy and
was excluded from further analyses (participant K, HAB
scanned with [11C]PBR28). Mean whole brain baseline VT for
the remaining [11C]PBR28 participants was 5.43 ± 1.68 ml/cm3.
Method 1a, the unconstrained occupancy plot, gave a mean VND
of 0.18 ± 0.05 ml/cm3 for [18F]GE-180 and 3.65 ± 1.79 ml/cm3
for [11C]PBR28. Method 1b, using an occupancy plot and
constraining the x-intercept across participants, gave mean VND
Fig. 1 Hammers atlas filled with VT results in transverse view a pre- and b post-XBD173 administration, for participant F
scanned with [18F]GE-180. VT (ml/cm
3) for each region is mapped onto the participant’s regional atlas in patient space. Sum
60–90 min PET images (kBq ml−1) for the same subject in transverse view c pre- and d post-XBD173 administration. e T1 MRI
for same subject.
Fig. 2 Hammers atlas filled with VT results in transverse view a pre- and b post-XBD173 administration, for participant H
scanned with [11C]PBR28. VT (ml/cm
3) for each region is mapped onto the participant’s regional atlas in patient space. Sum 60–
90 min PET images (kBq ml−1) for the same subject in transverse view c pre- and d post-XBD173 administration. e T1 MRI for
same subject.
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estimates of 0.11 and 3.81 ml/cm3 respectively. Method 2, using
a polymorphism plot, produced VND estimates of 0.20 and
3.49 ml/cm3, respectively (Figs. 3 and 4). With VND estimates of
0.16 ± 0.05ml/cm3 (mean of the threemethods) for [18F]GE-180
and 3.65 ± 0.16 ml/cm3 for [11C]PBR28 and mean baseline
whole brain VT of 0.29 and 5.43 ml/cm
3, respectively, the
specific binding (VS = VT −VND) accounted for 45 % of total
VT in the brain for [
18F]GE-180 (57 % HABs; 20 %MABs) and
33 % for [11C]PBR28 (37 % HABs; 25 % MABs). The
reduction in uptake for both tracers post-XBD173 administration
is further highlighted in Fig. 5, where a clear decrease inVT in the
majority of ROIs is observed. Furthermore, BPND (¼ VTVND−1)
was used to calculate the mean HAB/MAB signal ratio for each
tracer using these mean VND values. For [
18F]GE-180, this was
5.45 ± 3.29 (p G 0.01), while for [11C]PBR28, the HAB/MAB
ratio was 3.21 ± 1.27 (p G 0.01).
Specific Binding to TSPO Is Ubiquitous in the MS
Brain
For [18F]GE-180, VS accounted for between 39 % (striatum)
and 54 % (thalamus) of total binding in the selected ROIs
(mean ± SD, 45 ± 5 %). For [11C]PBR28, VS accounted for
between 6 % (striatum) and 43 % (brainstem) of total
binding (29 ± 11 %). All other ROIs defined by the
Hammers atlas, including the caudate and non-cortical GM,
exhibited mean VT between 0.25 and 0.56 ml/cm
3 and
between 3.99 and 7.39 ml/cm3, respectively. Thus, it follows
that no ROIs were consistently devoid of specific TSPO
binding, as measured by either tracer.
Discussion
This study was designed to quantify the non-specific binding
(VND) of the TSPO PET tracers [
18F]GE-180 and
[11C]PBR28 in people with MS. We found that VND
accounts for, on average, 55 and 67 % of the total binding
of [18F]GE-180 and [11C]PBR28, respectively, indicating
that the remaining 45 or 33 % are attributable to specific
signal (VS).
[18F]GE-180 has shown high signal-to-noise ratios in
preclinical studies [10–12, 21, 22] but unexpectedly low
brain penetration in human healthy controls [13–15]. Recent
studies have demonstrated markedly increased uptake of
[18F]GE-180 in people with glioblastoma [23] and in people
Fig. 3 a Individual linear regression with occupancy plot, b constrained x-intercept occupancy plot and c polymorphism plot,
bottom for [18F]GE-180. VND is derived from the x-intercept. Different symbols indicate individual patients for a and b; each
symbol represents a region of interest.
Fig. 4 a Individual linear regression with occupancy plot, b constrained x-intercept occupancy plot and c polymorphism plot,
bottom for [11C]PBR28. VND is derived from the x-intercept. Different symbols indicate individual patients for a and b; each
symbol represents a region of interest.
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with relapsing-remitting MS [24], but questions remain as to
whether this increase in signal represents specific binding or
is merely due to non-specific signal in areas of blood−brain
barrier breakdown. Another recent study which directly
compared [18F]GE-180 with [11C]PBR28 in healthy controls
who were scanned with both tracers (morning and afternoon)
found up to 20 times lower volumes of distribution with the
former compared to the latter [15] as well as difficulties with
[18F]GE-180 quantification. To our knowledge, ours is the
first study assessing non-displaceable binding of [18F]GE-
180 and comparing both tracers in disease cohorts. Our
results argue that, despite low brain penetration [13, 14],
[18F]GE-180 does exhibit a specific signal in the MS brain
and hence could be useful in conditions with pathologically
increased levels of TSPO. We also performed gadolinium
contrast-enhancing MRI in the cohort of participants
scanned with [18F]GE-180 and observed no contrast en-
hancement (in lesion areas or otherwise), suggesting no
extensive BBB breakdown. Although this observation does
not exclude the possibility of micro-BBB breakdown, which
could allow passage of [18F]GE-180 molecules, but not the
larger gadolinium molecules, through the disrupted area, the
finding does concur with that of Vomacka et al. [25]. The
authors of this study also comment that (in their previous
study [23]) areas with contrast enhancement in MR did not
always correlate with increased [18F]GE-180 signal, indicat-
ing that signal increases in PET are likely to be related to
TSPO expression rather than exclusively BBB breakdown.
The results also have broader implications on how novel
tracers should be validated and compared. While high
absolute VTs are preferable in a tracer, it is crucial to
understand what proportion of VT is driven by VND. This can
be achieved using a blocking study, which, given the lack of
an appropriate receptor-free reference region in the brain, we
suggest should be undertaken for all TSPO tracers undergo-
ing clinical development.
Although the occupancy plot has been more commonly
used in VND quantification [4], an alternative approach,
relevant for TSPO tracers which are susceptible to the
rs6971 SNP, is to create a polymorphism plot, which does
not require pharmacological blockade and relies only on the
assumption of equal expression of HAB and LAB sites. Our
Fig. 5 Bar graph plots of average regional VT pre- and post-blockade for HABs and MABs for a and b: [
18F]GE-180; c and d:
[11C]PBR28. e and f: HAB vs. MAB group VT estimates for each tracer (n = 6 [
18F]GE-180; n = 5 [11C]PBR28).
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VND results from both methods (including free and fixed-
intercept occupancy plots) were in good agreement for both
tracers, giving an average VND of 0.16 ± 0.05 ml/cm
3 for
[18F]GE-180 and 3.65 ± 0.16 ml/cm3 for [11C]PBR28. In this
study, we also demonstrate that VT is consistently greater
than VND for both [
18F]GE-180 and [11C]PBR28; in other
words, no ROIs were devoid of specific TSPO binding. This
finding fits with previous observations that reference tissue
approaches may not be appropriate in TSPO PET studies [6].
[11C]PBR28 has been validated with blocking experi-
ments prior to our study, both in healthy controls [6, 26] and
in a disease cohort [27]. [11C]PBR28 is generally accepted
as an effective TSPO tracer in vivo [28–32] although
exhibits counterintuitively decreased VT in subjects with
neuroinflammation [29]. In Owen et al. [6], the VND of
[11C]PBR28 was 1.98 ml/cm3 (~ 50 % of VT), while Fujita
et al. [26] reported an average VT of 4.3 ml/cm
3 (in HABs)
and a BPND of 1.2, giving a very similar VND of 1.98 ml/cm
3
(~ 45 % of VT). In our study, VND for [
11C]PBR28 was 3.65.
It is possible that this is a disease-specific difference, given
that both the former studies were performed in healthy
subjects; however, the sample size in our study was also
small and the estimation of VND may therefore be subject to
some biological variability. Nevertheless, the proportion of
non-specific binding for [18F]GE-180 is comparable to or
even lower than that of [11C]PBR28 (VND ~ 55 vs. ~69 %,
respectively), although absolute VTs are lower [6, 27]. This
result further indicates that [18F]GE-180 is able to identify
specific TSPO signal in the MS brain, in spite of low brain
penetration. We also report respective HAB and MAB VS of
57 and 20 % for [18F]GE-180 and 37 and 25 % for
[11C]PBR28, although the group numbers (n = 3 for both
[18F]GE-180 groups and [11C]PBR28 HABs, n = 2 for
[11C]PBR28 MABs) are too small to draw firm conclusions.
As has been pointed out previously, the brain penetration
of [18F]GE-180 is very low in humans [13–15]. Our
findings also showed low values of VT and K1, indicating
low extraction of the tracer across the blood−brain barrier
(K1 ~ 0.003 vs. 0.2 ml/cm
3/min for [11C]PBR28; i.e., ~ 60×
lower). Zanotti-Fregonara and colleagues also noted diffi-
culty in kinetic model fitting of [18F]GE-180 data using the
standard two-tissue compartment model with free blood
volume parameter, which we used [15]. Here, however, we
were able to fit the large majority of regions well, with R2
comparable to those seen with [11C]PBR28 (R2 ~ 0.8) and
standard errors on VT estimates G 20 % for both tracers. It is
possible that this is due to the larger, less noisy ROIs
selected for analysis in our study compared to those used by
Zanotti-Fregonara and colleagues. Also to be considered is
the fact that our study involved (six) participants with MS,
compared to the four healthy controls and single participant
with amytrophic lateral sclerosis in the other study, which
may have resulted in altered binding kinetics due to disease-
specific pathology. Although a methodology considering
large ROIs in a disease such as MS, with focal lesion-based
pathology, may seem to limit the usefulness of a tracer,
there is evidence that there is a global effect on TSPO PET
signal in regions such as NAWM and normal appearing
grey matter (see [33] for review), suggesting that [18F]GE-
180 need not be excluded from use based on this fact. Many
recent studies using [11C]PBR28 (and other tracers) have
elected to use the 2TCM-1K kinetic model [34], which
incorporates a parameter representing the endothelial
fraction of binding of a TSPO tracer, for quantification
[29]. The 2TCM-1K has been used with [18F]GE-180 data
[13] and has not shown a substantial advantage in terms of
parsimony criteria (Akaike Information Criteria, AIC)
compared to the 2TCM. Furthermore, [11C]PBR28 datasets
are often still analysed using the 2TCM, primarily for
comparison with data from other tracers [15, 35, 36]. We
also found good fits to [11C]PBR28 data with the 2TCM;
thus, here, we elected to use this model to analyse data from
both tracers.
The in vitro HAB/LAB ratio of binding affinity for
[11C]PBR28 has been observed to be approximately 1:50
[9], while for [18F]GE-180, this ratio is between 1:5 and 1:15
(personal communication, DRO, WT). In vivo, [11C]PBR28-
scanned MABs express approximately half the signal
compared to HABs [6]. The slope of the polymorphism plot
is equivalent to BP
HAB
ND −BP
MAB
ND
BPHABND
. For [18F]GE-180, our equivalent
in vivo HAB/MAB ratio was found to be 5.43 ± 3.27 and the
average slope was thus expected to be approximately 0.8,
while for [11C]PBR28, these values were 3.21 ± 1.27 and
0.7. Our results for the slopes of the polymorphism plots
were 0.96 and 0.67 respectively and thus fell within one
standard deviation of the predicted values. Previous studies
using [18F]GE-180 have been unable to detect consistent
differences in tracer signal between HABs and MABs [13,
14, 24], indicating that brain penetration of the tracer is low,
except where BBB breakdown may be present [24].
Contrary to these results, in our study, HABs exhibited
approximately twice the total volume of distribution of
MABs in selected ROIs at baseline. It is likely that the
difference in our study is driven primarily by one HAB with
particularly high signal (participant D) and one MAB with
particularly low signal (participant E). Clearly there is
considerable variability in population VT and with the small
sample size in our study (n = 6), we are unable to validate
our findings with statistical tests. In addition, the difference
in scan timing between the first and second (post-XBD173)
scan varied for each tracer (half a day for [11C]PBR28 and
1 week for [18F]GE-180), which itself may have introduced
some variability in PET signal. Thus, we suggest continuing
binding status stratification of participants in future studies,
where larger data pools may enable more reliable HAB/
MAB binding ratio estimates.
Several caveats exist in this study. Firstly, the occu-
pancy of XBD173 in the two cohorts (slopes in the
occupancy plots) varied between 24 and 95 % (fixed-
intercept plot) for [18F]GE-180 and 16 and 220 % for
[11C]PBR28. Clearly, the occupancy of XBD173 cannot
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exceed 100 %, and indeed, the dose administered was pre-
calculated to give an expected approximate 75 % occu-
pancy, allowing for participant weights and considering the
dose-occupancy relationship described by Owen et al. [6]
for [11C]PBR28. Of course, it should also be noted that
these values were obtained from the fixed-intercept
occupancy plot; for the free intercept plot, occupancies
were within one standard deviation of the expected value.
This point again highlights the large variability across
cohorts and the fact that averaging results across partici-
pants, even within the same disease population, may not be
a suitable approach. In addition, one participant scanned
with [11C]PBR28 exhibited no substantial occupancy and
was excluded from further analysis. This large inter-
individual variability in occupancy was also seen in
previous XBD173 blocking studies [6, 27], reflected in
the variability in total signal reduction (VT) between pre
and post-block scans. Whether driven by biological
variability or experimental noise, these results provide
evidence that VND cannot necessarily be assumed to be the
same across regions and a population. If there is indeed a
biological spectrum of VND between individuals, this raises
the interesting possibility that blocking scans should be
included for all participants in all TSPO PET studies to
optimally quantify VS. This would have broad repercus-
sions on TSPO PET study design, including cost, radiation
exposure and participant discomfort. All neuro-PET tracers
are, of course, better able to penetrate brain tissue when the
BBB is disrupted. In the case of [18F]GE-180, which
exhibits low penetration of the healthy BBB, this is
particularly relevant. Although our cohorts were selected
due to their clinically low or ‘inactive’ MRI, and although
we investigated only lesion-free ROIs, we only performed
contrast enhanced MRI to estimate BBB integrity in the
[18F]GE-180 cohort, and no measure of micro-BBB
disruption was performed. Lastly, although this study was
performed in a cohort of people with MS, we have not
investigated how VT differs in MS lesions or how it
correlates with clinical outcomes. This study was not
powered to address these questions, since participants were
not burdened with large lesion loads. Instead, these
questions will be explored in follow-up studies.
Conclusion
In summary, pharmacological blockade with XBD173
demonstrates, for the first time in vivo, that [18F]GE-180
does bind specifically to TSPO in normal appearing white
and grey matter, to an extent that is highly comparable to
[11C]PBR28, in spite of the low extraction fraction of the
former.
Acknowledgements. The authors wish to thank Dr. William Trigg (formerly
GE Healthcare), Dr. Christopher Buckley and Ms. Joanne Stevens (GE
Healthcare) and Professor Federico Turkheimer (King’s College London)
for their valuable advice during the analysis and write-up of this study.
Funding Information. This [18F]GE-180 arm of the study was funded by
grants from GE Healthcare, FastForward and the MSTC, awarded to the
Imperial College Trust. The [11C]PBR28 arm of the study was funded by an
Imperial College BRC IMPETUS 2014 grant.
Compliance with Ethical Standards
Conflict of Interest
SS, RN and JR have received funding from GE Healthcare. JR is a current
employee of the MHRA; work herein was completed while JR was
employed by Imperial College.
PAM declares honoraria for speaking and travel support from Bayer,
Biogen, Merck Serono and Novartis.
DJB holds consultancies with GE Healthcare and Biogen.
RG is an employee of Invicro, Ltd.
All other authors have no disclosures.
Open Access This article is distributed under the terms of the Creative
Commons At t r i bu t ion 4 .0 In t e rna t i ona l L i c en se (h t t p : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appropri-
ate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J,
Akula N, Groyer G, Adams D, Schumacher M et al (2010)
Translocator protein (18 kDa) (TSPO) as a therapeutic target for
neurological and psychiatric disorders. Nat Rev Drug Discov
9:971–988
2. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A,
Rhodes C, Pulford DJ, Bennacef I, Parker CA, StJean PL, Cardon LR,
Mooser VE, Matthews PM, Rabiner EA, Rubio JP et al (2012) An 18-
kDa translocator protein (TSPO) polymorphism explains differences
in binding affinity of the PET radioligand PBR28. J Cereb Blood
Flow Metab 32:1–5
3. Turkheimer FE, Rizzo G, Bloomfield PS, Howes O, Zanotti-
Fregonara P, Bertoldo A, Veronese M et al (2015) The methodology
of TSPO imaging with positron emission tomography. Biochem Soc
Trans 43:586–592
4. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN et al
(2010) Measuring drug occupancy in the absence of a reference
region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30:46–
50
5. Lassen NA, Bartenstein PA, Lammertsma AA, Prevett MC, Turton
DR, Luthra SK, Osman S, Bloomfield PM, Jones T, Patsalos PN,
O'Connell MT, Duncan JS, Andersen JV et al (1995) Benzodiazepine
receptor quantification in vivo in humans using [11C] flumazenil and
PET: application of the steady-state principle. J Cereb Blood Flow
Metab 15:152–165
6. Owen DR, Guo Q, Kalk NJ, Colasanti A, Kalogiannopoulou D,
Dimber R, Lewis YL, Libri V, Barletta J, Ramada-Magalhaes J,
Kamalakaran A, Nutt DJ, Passchier J, Matthews PM, Gunn RN,
Rabiner EA et al (2014) Determination of [11C]PBR28 binding
potential in vivo: a first human TSPO blocking study. J Cereb Blood
Flow Metab 34:989–994
7. Guo Q, Colasanti A, Owen DR, Onega M, Kamalakaran A, Bennacef
I, Matthews PM, Rabiner EA, Turkheimer FE, Gunn RN et al (2013)
Quantification of the specific translocator protein signal of 18F-
PBR111 in healthy humans: a genetic polymorphism effect on in vivo
binding. J Nucl Med 54:1915–1923
8. Guo Q, Owen DR, Rabiner EA, Turkheimer FE, Gunn RN (2014) A
graphical method to compare the in vivo binding potential of PET
radioligands in the absence of a reference region: application to
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Sridharan S. et al.: [18F]GE-180 Specific Binding
[11C]PBR28 and [18F]PBR111 for TSPO imaging. J Cereb Blood
Flow Metab 34:1162–1168
9. Owen DR, Howell OW, Tang SP, Wells LA, Bennacef I, Bergstrom
M, Gunn RN, Rabiner EA, Wilkins MR, Reynolds R, Matthews PM,
Parker CA et al (2010) Two binding sites for [3H]PBR28 in human
brain: implications for TSPO PET imaging of neuroinflammation. J
Cereb Blood Flow Metab 30:1608–1618
10. Boutin H, Murray K, Pradillo J, Maroy R, Smigova A, Gerhard A,
Jones PA, Trigg W et al (2015) 18F-GE-180: a novel TSPO radiotracer
compared to 11C-R-PK11195 in a preclinical model of stroke. Eur J
Nucl Med Mol Imaging 42:503–511
11. Dickens AM, Vainio S, Marjamaki P, Johansson J, Lehtiniemi P,
Rokka J, Rinne J, Solin O, Haaparanta-Solin M, Jones PA, Trigg W,
Anthony DC, Airas L et al (2014) Detection of microglial activation in
an acute model of neuroinflammation using PET and radiotracers
C-11-(R)-PK11195 and F-18-GE-180. J Nucl Med 55:466–472
12. James ML, Belichenko NP, Shuhendler AJ, Hoehne A, Andrews LE,
Condon C, Nguyen TVV, Reiser V, Jones P, Trigg W, Rao J,
Gambhir SS, Longo FM et al (2017) [18F]GE-180 PET detects
reduced microglia activation after LM11A-31 therapy in a mouse
model of Alzheimer's disease. Theranostics 7:1422–1436
13. Fan Z, Calsolaro V, Atkinson RA, Femminella GD, Waldman A,
Buckley C, Trigg W, Brooks DJ, Hinz R, Edison P et al (2016)
Flutriciclamide (18F-GE180) PET: first-in-human PET study of novel
third-generation in vivo marker of human translocator protein. J Nucl
Med 57:1753–1759
14. Feeney C, Scott G, Raffel J, Roberts S, Coello C, Jolly A, Searle G,
Goldstone AP, Brooks DJ, Nicholas RS, Trigg W, Gunn RN, Sharp
DJ et al (2016) Kinetic analysis of the translocator protein positron
emission tomography ligand [18F]GE-180 in the human brain. Eur J
Nucl Med Mol Imaging 43:2201–2210
15. Zanotti-Fregonara P, Pascual B, Rizzo G et al (2018) Head-to-head
comparison of 11C-PBR28 and 18F-GE180 for the quantification of
TSPO in the human brain. In J Nucl Med 59(8):1260–1266
16. Owen DRJ, Gunn RN, Rabiner EA, Bennacef I, Fujita M, Kreisl WC,
Innis RB, Pike VW, Reynolds R, Matthews PM, Parker CA et al
(2011) Mixed-affinity binding in humans with 18-kDa translocator
protein ligands. J Nucl Med 52:24–32
17. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis:
an expanded disability status scale (EDSS). Neurology 33:1444–1452
18. Wadsworth H, Jones PA, Chau WF, Durrant C, Fouladi N, Passmore
J, O’Shea D, Wynn D, Morisson-Iveson V, Ewan A, Thaning M,
Mantzilas D, Gausemel I, Khan I, Black A, Avory M, Trigg W et al
(2012) [18F]GE-180: a novel fluorine-18 labelled PET tracer for
imaging translocator protein 18 kDa (TSPO). Bioorg Med Chem Lett
22:1308–1313
19. Hammers A, Allom R, Free SL et al (2002) Three-dimensional
probabilistic atlas of the human brain. Neuroimage 16:S86–S86
20. Watabe H, Channing MA, Der MG et al (2000) Kinetic analysis of the
5-HT2A ligand [11C] MDL 100,907. J Cereb Blood Flow Metab
20:899–909
21. Sridharan S, Lepelletier FX, Trigg W, Banister S, Reekie T, Kassiou
M, Gerhard A, Hinz R, Boutin H et al (2017) Comparative evaluation
of three TSPO PET radiotracers in a LPS-induced model of mild
neuroinflammation in rats. Mol Imaging Biol 19:77–89
22. Russmann V, Brendel M, Mille E, Helm-Vicidomini A, Beck R,
Günther L, Lindner S, Rominger A, Keck M, Salvamoser JD, Albert
NL, Bartenstein P, Potschka H et al (2017) Identification of brain
regions predicting epileptogenesis by serial [18F]GE-180 positron
emission tomography imaging of neuroinflammation in a rat model of
temporal lobe epilepsy. Neuroimage Clin 15:35–44
23. Albert NL, Unterrainer M, Fleischmann DF, Lindner S, Vettermann F,
Brunegraf A, Vomacka L, Brendel M, Wenter V, Wetzel C,
Rupprecht R, Tonn JC, Belka C, Bartenstein P, Niyazi M et al
(2017) TSPO PET for glioma imaging using the novel ligand 18F-GE-
180: first results in patients with glioblastoma. Eur J Nucl Med Mol
Imaging 44:2230–2238
24. Unterrainer M, Mahler C, Vomacka L, Lindner S, Havla J, Brendel M,
Böning G, Ertl-Wagner B, Kümpfel T, Milenkovic VM, Rupprecht R,
Kerschensteiner M, Bartenstein P, Albert NL et al (2018) TSPO PET
with [(18)F]GE-180 sensitively detects focal neuroinflammation in
patients with relapsing-remitting multiple sclerosis. Eur J Nucl Med
Mol Imaging 45:1423–1431
25. Vomacka L, Albert NL, Lindner S, Unterrainer M, Mahler C, Brendel
M, Ermoschkin L, Gosewisch A, Brunegraf A, Buckley C, Kümpfel
T, Rupprecht R, Ziegler S, Kerschensteiner M, Bartenstein P, Böning
G et al (2017) TSPO imaging using the novel PET ligand [18F]GE-
180: quantification approaches in patients with multiple sclerosis.
EJNMMI Res 7:89
26. Fujita M, Kobayashi M, Ikawa M, Gunn RN, Rabiner EA, Owen DR,
Zoghbi SS, Haskali MB, Telu S, Pike VW, Innis RB et al (2017)
Comparison of four 11C-labeled PET ligands to quantify translocator
protein 18 kDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-
713, and ER176-based on recent publications that measured specific-
to-non-displaceable ratios. EJNMMI Res 7:84
27. Veronese M, Reis Marques T, Bloomfield PS, Rizzo G, Singh N,
Jones D, Agushi E, Mosses D, Bertoldo A, Howes O, Roncaroli F,
Turkheimer FE et al (2018) Kinetic modelling of [11C]PBR28 for
18 kDa translocator protein PET data: a validation study of vascular
modelling in the brain using XBD173 and tissue analysis. J Cereb
Blood Flow Metab 38:1227–1242
28. Albrecht D, Shcherbinin S, Wooten D et al (2016) Occipital lobe as a
pseudo-reference region for [11C]PBR28 PET imaging: validation in
chronic pain and amyotrophic lateral sclerosis cohorts. J Nucl Med
57:1814
29. Bloomfield PS, Selvaraj S, Veronese M, Rizzo G, Bertoldo A, Owen
DR, Bloomfield MAP, Bonoldi I, Kalk N, Turkheimer F, McGuire P,
de Paola V, Howes OD et al (2016) Microglial activity in people at
ultra high risk of psychosis and in schizophrenia: an [11C]PBR28 PET
brain imaging study. Am J Psychiatry 173:44–52
30. Datta G, Colasanti A, Kalk N, Owen D, Scott G, Rabiner EA, Gunn
RN, Lingford-Hughes A, Malik O, Ciccarelli O, Nicholas R, Nei L,
Battaglini M, Stefano ND, Matthews PM et al (2017) 11C-PBR28 and
18F-PBR111 detect white matter inflammatory heterogeneity in
multiple sclerosis. J Nucl Med 58:1477–1482
31. Kreisl WC, Fujita M, Fujimura Y, Kimura N, Jenko KJ, Kannan P,
Hong J, Morse CL, Zoghbi SS, Gladding RL, Jacobson S, Oh U, Pike
VW, Innis RB et al (2010) Comparison of [11C]-(R)-PK 11195 and
[11C]PBR28, two radioligands for translocator protein (18 kDa) in
human and monkey: implications for positron emission tomographic
imaging of this inflammation biomarker. Neuroimage 49:2924–2932
32. Park E, Gallezot JD, Delgadillo A, Liu S, Planeta B, Lin SF,
O’Connor KC, Lim K, Lee JY, Chastre A, Chen MK, Seneca N,
Leppert D, Huang Y, Carson RE, Pelletier D et al (2015) 11C-PBR28
imaging in multiple sclerosis patients and healthy controls: test-retest
reproducibility and focal visualization of active white matter areas.
Eur J Nucl Med Mol Imaging 42:1081–1092
33. Airas L, Nylund M, Rissanen E (2018) Evaluation of microglial
activation in multiple sclerosis patients using positron emission
tomography. Front Neurol 9:181
34. Rizzo G, Veronese M, Tonietto M, Zanotti-Fregonara P, Turkheimer
FE, Bertoldo A et al (2014) Kinetic modeling without accounting for
the vascular component impairs the quantification of [11C]PBR28
brain PET data. J Cereb Blood Flow Metab 34:1060–1069
35. Collste K, Forsberg A, Varrone A, Amini N, Aeinehband S, Yakushev
I, Halldin C, Farde L, Cervenka S et al (2016) Test-retest
reproducibility of [C-11]PBR28 binding to TSPO in healthy control
subjects. Eur J Nucl Med Mol Imaging 43:173–183
36. Collste K, Plaven-Sigray P, Fatouros-Bergman H et al (2017) Lower
levels of the glial cell marker TSPO in drug-naive first-episode
psychosis patients as measured using PET and [11C]PBR28. Mol
Psychiatry 22:850–856
Sridharan S. et al.: [18F]GE-180 Specific Binding
